Arcadia Biosciences, Inc. (RKDA) Financial Ratios
14 years of historical data (2012–2025) · Basic Materials · Agricultural Inputs
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.26
↓-61% vs avg
5yr avg: 0.66
30Y Low0.3·High4.2
ROE
↑
-45.1%
↓+27% vs avg
5yr avg: -62.2%
30Y Low-273%·High-25%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
RKDA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Arcadia Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1M | $3M | $8M | $4M | $6M | $22M | $25M | $35M | $12M | $12M | $41M |
| Enterprise Value | $943884 | $2M | $4M | $-1639397 | $-12129623 | $-3259176 | $21M | $29M | $-58512 | $3M | $64M |
| P/E Ratio → | -0.45 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.25 | 0.56 | 1.60 | 0.87 | 0.88 | 3.26 | 3.14 | 29.83 | 8.16 | 2.95 | 12.80 |
| P/B Ratio | 0.26 | 0.65 | 1.30 | 0.30 | 0.31 | 0.71 | 0.88 | 4.19 | 0.93 | 1.48 | 1.84 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
RKDA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.50 | 0.79 | -0.37 | -1.64 | -0.48 | 2.55 | 24.54 | -0.04 | 0.68 | 20.05 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
RKDA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Arcadia Biosciences, Inc. earns an operating margin of -205.7%, below the Basic Materials sector average of 10.3%. Operating margins have compressed from -137.0% to -205.7% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -45.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 36.2% | 36.2% | 41.3% | 51.2% | 17.8% | -28.4% | 35.3% | 24.3% | 54.8% | 93.0% | 71.9% |
| Operating Margin | -205.7% | -205.7% | -72.3% | -137.0% | -188.8% | -524.0% | -159.0% | -1657.9% | -1152.3% | -355.6% | -584.1% |
| Net Profit Margin | -48.1% | -48.1% | -139.5% | -313.9% | -207.3% | -216.2% | -57.9% | -2464.1% | -920.8% | -390.1% | -615.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -45.1% | -45.1% | -74.4% | -83.2% | -59.0% | -49.1% | -25.2% | -272.5% | -129.5% | -104.0% | -62.9% |
| ROA | -23.3% | -23.3% | -42.4% | -57.5% | -42.2% | -32.1% | -11.6% | -101.8% | -66.4% | -42.9% | -30.0% |
| ROIC | -249.2% | -249.2% | -58.7% | -96.7% | -260.1% | -179.6% | -73.7% | -980.5% | -1548.7% | -48.6% | -32.3% |
| ROCE | -129.5% | -129.5% | -27.0% | -29.9% | -44.1% | -88.9% | -37.6% | -81.0% | -99.2% | -43.1% | -30.0% |
RKDA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $259000 exceeds total debt of $0, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.02 | 0.08 | 0.10 | 0.11 | 0.33 | 0.27 | — | — | 1.13 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.06 | -0.66 | -0.43 | -0.89 | -0.81 | -0.16 | -0.74 | -0.94 | -1.14 | 1.04 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -1437.75 | -129.85 | -5773.20 | -5.27 | -19.99 | -13.86 |
Net cash position: cash ($259000) exceeds total debt ($0)
RKDA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Arcadia Biosciences, Inc.'s current ratio of 3.09x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 2.50x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 4.17x to 3.09x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.09 | 3.09 | 3.61 | 4.17 | 6.03 | 7.02 | 5.02 | 4.98 | 7.49 | 4.27 | 16.69 |
| Quick Ratio | 2.50 | 2.50 | 3.25 | 3.63 | 5.48 | 6.14 | 4.42 | 4.67 | 7.43 | 4.20 | 16.61 |
| Cash Ratio | 2.22 | 2.22 | 1.66 | 3.24 | 4.90 | 5.69 | 4.07 | 4.44 | 7.15 | 3.69 | 16.16 |
| Asset Turnover | — | 0.74 | 0.37 | 0.23 | 0.26 | 0.15 | 0.17 | 0.04 | 0.06 | 0.24 | 0.06 |
| Inventory Turnover | 2.56 | 2.56 | 3.28 | 1.11 | 2.63 | 1.96 | 1.36 | 0.49 | 3.65 | 1.24 | 3.55 |
| Days Sales Outstanding | — | 31.93 | 85.01 | 42.12 | 60.08 | 73.75 | 63.88 | 187.96 | 41.89 | 111.97 | 61.02 |
RKDA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Arcadia Biosciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $1M | $1M | $1M | $599389 | $532015 | $248975 | $159077 | $94160 | $53905 | $55458 |
Peer Comparison
Compare RKDA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 RKDAYou | $1M | -0.5 | — | — | 36.2% | -205.7% | -45.1% | -249.2% | — |
 PGEN | $1B | -3.4 | — | — | 37.1% | -1100.8% | -843.6% | -1553.8% | — |
 OFIX | $382M | -4.1 | — | — | 67.1% | -8.3% | -19.3% | -8.6% | — |
 SEED | $7M | -1.0 | — | — | 7.0% | -58.9% | — | — | — |
 CTVA | $53B | 49.1 | 13.3 | 18.7 | 43.6% | 15.1% | 4.5% | 8.5% | 0.7 |
 FMC | $1B | -0.6 | — | — | 37.0% | -54.4% | -67.8% | -21.2% | — |
 BIOX | $24M | -0.5 | 19.5 | 0.7 | 39.1% | -1.1% | -16.0% | -0.5% | 20.2 |
 NUVL | $9B | -21.1 | — | — | — | — | -36.7% | -32.5% | — |
 AMTX | $134M | -1.5 | — | — | -0.4% | -17.9% | — | -70.3% | — |
 ADM | $36B | 33.7 | 16.7 | 8.6 | 6.3% | 1.8% | 4.7% | 3.3% | 3.2 |
 BG | $22B | 22.9 | 21.4 | — | 4.5% | 1.5% | 5.8% | 3.3% | 9.6 |
| Basic Materials Median | — | 23.6 | 11.0 | 29.0 | 30.9% | 10.3% | -0.0% | 4.6% | 2.4 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
RKDA — Frequently Asked Questions
Quick answers to the most common questions about buying RKDA stock.
What is Arcadia Biosciences, Inc.'s P/E ratio?
Arcadia Biosciences, Inc.'s current P/E ratio is -0.5x. This places it at the 50th percentile of its historical range.
What is Arcadia Biosciences, Inc.'s ROE?
Arcadia Biosciences, Inc.'s return on equity (ROE) is -45.1%. The historical average is -90.8%.
Is RKDA stock overvalued?
Based on historical data, Arcadia Biosciences, Inc. is trading at a P/E of -0.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Arcadia Biosciences, Inc.'s profit margins?
Arcadia Biosciences, Inc. has 36.2% gross margin and -205.7% operating margin.